Details of Drug-Drug Interaction
| Drug General Information (ID: DDIRO3D6PT) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Safinamide | Drug Info | Tetryzoline (ophthalmic) | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Dopaminergic Antiparkinsonism Agents | Alpha-Adrenergic Agonists | |||||||
| Structure | |||||||||
| Mechanism of Safinamide-Tetryzoline (ophthalmic) Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Non-CYP450 enzyme inhibition Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Safinamide | Tetryzoline (ophthalmic) | |||||||
| Mechanism | Monoamine oxidase inhibitor | Monoamine oxidase substrate | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Monoamine oxidase | Structure Sequence | |||||||
| Protein Family | Flavin monoamine oxidase family | ||||||||
| Protein Function |
Catalyzes the oxidative deamination of primary and some secondary amine such as neurotransmitters, with concomitant reduction of oxygen to hydrogen peroxide and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues (PubMed:20493079, PubMed:8316221, PubMed:18391214, PubMed:24169519). Preferentially oxidizes serotonin (PubMed:20493079, PubMed:24169519). Also catalyzes the oxidative deamination of kynuramine to 3-(2-aminophenyl)-3-oxopropanal that can spontaneously condense to 4-hydroxyquinoline (By similarity).
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Caution and more frequent blood pressure monitoring may be advisable when oral and/or topical sympathomimetic agents are coadministered with MAOIs including safinamide. | ||||||||